The trials are designed to establish the optimal dosage of four mRNA candidates, each representative of a unique combination of mRNA format and target antigen, so that the safest candidate can be used in mass production.
Designed to prevent COVID-19, Pfizer and BioNTech’s BNT162 vaccine program began dosing patients in Germany in late April. Phase ½ is underway in the U.S., with patients being dosed at New York City-based NYU Grossman School of Medicine and Baltimore-based University of Maryland School of Medicine. Soon, the University of Rochester Medical Center/Rochester Regional Health and Cincinnati Children’s Hospital Medical Center will also become trial sites.
Pfizer and BioNTech have been increasing production for global supply, planning to produce millions of vaccine doses this year and hundreds of millions in 2021.
More articles on pharmacy:
6 federal pharmacy policy changes in response to the COVID-19 pandemic
Clinical trials for COVID-19 drugs & when to expect results
Walgreens lowers prices on hundreds of prescription drugs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.